Improving COPD Outcomes: Using Real-World Data to Analyze Treatment Effectiveness, Safety, and Adherence

改善慢性阻塞性肺病的治疗效果:使用真实世界数据分析治疗效果、安全性和依从性

基本信息

  • 批准号:
    10590302
  • 负责人:
  • 金额:
    $ 16.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-19 至 2027-11-30
  • 项目状态:
    未结题

项目摘要

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality worldwide and is associated with symptoms of dyspnea, cough, and reduced functional capacity. While numerous scientific advances have been made to improve the care of patients with COPD, considerable uncertainty remains about optimal management. For some questions, clinical trial data have been conflicting; for others, clinical trials have not been feasible. Uncertainty in the management of COPD has been further compounded by questions of generalizability in randomized controlled trials. Studies have demonstrated that the majority of patients with COPD would not qualify for such trials because of their strict inclusion criteria based on characteristics such as age, comorbidities, smoking status, and spirometry. Conflicting or absent clinical trial data and questions of generalizability prompt the need for “real-world” studies of patients treated for COPD in routine clinical practice. Given poor adherence to inhaler therapy outside of clinical trials, studies are also needed to understand why patients discontinue therapy. Improving the care of patients with COPD requires identifying which therapies are most likely to be safe and effective in routine clinical practice and developing interventions to target those least likely to be adherent. The ultimate goal of the proposed research is to supplement existing data from randomized controlled trials with pharmacoepidemiologic studies to refine treatment strategies in COPD. The proposed research will accomplish this goal by using large, longitudinal healthcare databases to pursue three specific aims: (1) To validate claims-based definitions of COPD exacerbations; (2) To compare the effectiveness and safety of therapies in the management of COPD, focusing on four areas of ongoing clinical uncertainty; and (3) To develop a clinical prediction rule of inhaler adherence that incorporates key variables across several domains, from out-of-pocket costs and insurance benefit design to therapy-related features (e.g., frequency of dosing) and COPD disease severity. By addressing treatment effectiveness, safety, and adherence among patients treated in routine clinical practice, the proposed research will glean novel insights into the management of COPD, particularly for patients who are underrepresented in clinical trials, including older adults, racial and ethnic minorities, women, and those with complex co-morbidities. Dr. Feldman has a unique background as a practicing pulmonologist with public health experience. This K08 proposes an education plan that will help him build new skills in pharmacoepidemiology. He will receive mentorship from Dr. Sebastian Schneeweiss, a pioneer in pharmacoepidemiology, and Dr. Aaron Kesselheim, a leading authority on pharmaceutical policy and use, and will rely on a team of scientific advisors with expertise in machine learning (Dr. Joshua Lin), data management (Dr. Shirley Wang), biostatistics (Dr. Robert Glynn), geriatric prescribing (Dr. Jerry Avorn), and COPD epidemiology (Dr. Edwin Silverman). This award will provide Dr. Feldman with the tools needed to become an independent investigator.
慢性阻塞性肺疾病(COPD)是全球死亡的主要原因之一, 与呼吸困难、咳嗽和功能减退的症状有关。虽然许多科学 尽管在改善COPD患者的护理方面取得了进展,但仍存在相当大的不确定性, 优化管理对于某些问题,临床试验数据一直相互矛盾;对于其他问题,临床试验 是不可行的。COPD管理的不确定性因以下问题而进一步加剧 随机对照试验的普遍性。研究表明,大多数患者 COPD不符合此类试验的条件,因为其严格的入选标准基于以下特征, 年龄、合并症、吸烟状况和肺量测定。确认或缺失临床试验数据以及 普遍性提示需要在常规临床实践中对接受COPD治疗的患者进行“真实世界”研究。 考虑到临床试验以外的吸入器治疗依从性差,还需要进行研究以了解原因 患者停止治疗。改善COPD患者的护理需要确定哪些治疗方法 在常规临床实践中最有可能安全有效,并针对那些最不安全有效的患者制定干预措施。 很可能是粘附性的。拟议研究的最终目标是补充现有数据, 药物流行病学研究的随机对照试验,以完善COPD的治疗策略。 拟议的研究将通过使用大型纵向医疗保健数据库来实现这一目标, 追求三个具体目标:(1)验证基于索赔的COPD急性加重定义;(2)比较 治疗COPD的有效性和安全性,重点关注正在进行的四个领域 临床不确定性;(3)制定吸入器依从性的临床预测规则, 从自付费用和保险福利设计到治疗相关的多个领域的变量 特征(例如,给药频率)和COPD疾病严重程度。通过解决治疗有效性、安全性、 在常规临床实践中接受治疗的患者中,拟议的研究将收集新的 对COPD管理的见解,特别是对于在临床试验中代表性不足的患者, 包括老年人、少数种族和民族、妇女和患有复杂合并症的人。 费尔德曼博士有一个独特的背景,作为一个执业肺科医生与公共卫生经验。这 K 08提出了一个教育计划,将帮助他建立药物流行病学的新技能。他将获得 来自药物流行病学先驱塞巴斯蒂安施内维斯博士和亚伦凯塞尔海姆博士的指导, 制药政策和使用方面的领先权威,并将依靠一个科学顾问团队, 机器学习(约书亚林博士)、数据管理(王雪莉博士)、生物统计学(罗伯特 Glynn)、老年处方(Jerry Avorn博士)和COPD流行病学(Edwin Silverman博士)。这个奖项将 为费尔德曼博士提供成为独立调查员所需的工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Brand Feldman其他文献

William Brand Feldman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 16.25万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 16.25万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 16.25万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 16.25万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 16.25万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 16.25万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 16.25万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 16.25万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 16.25万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 16.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了